Table 2.
Characteristics of patients with Covid-19 with HFNO treatment in the infection ward.
| All patients (n = 41) | Step-Up (n = 20) | Step-Down (n = 21) | p-value | |
|---|---|---|---|---|
| Male sex, No, (%) | 33 (80) | 18 (90) | 15 (71) | 0.14 |
| Age, years | 68 ± 12(48–88) | 76 ± 9(52–88) | 62 ± 11(48–86) | 0.001 |
| BMI≥30 kg/m2, No. (%) | 4 (10) | 3 | 1 | 0.28 |
| Tobacco use, No. (%) | 6 (12) | 5 | 1 | 0.07 |
| Hypertension, No. (%) | 18 (44) | 9 | 9 | 0.9 |
| Diabetes, No. (%) | 9 (22) | 3 | 6 | 0.3 |
| Renal or/and liver failure, No. (%) | 6 (15) | 2 | 4 | 0.4 |
| Heart failure, No. (%) | 7 (17) | 4 | 3 | 0.6 |
| COPD, No. (%) | 5 (12) | 5 | 0 | 0.01 |
| CRPa mg/l | 150 (6–500) | 147 | 153 | 0.9 |
| Fibrin-D-dimera mg/l FEU | 3.7(0,25–35,1) | 3.7 | 3.7 | 0.9 |
| Duration of symptoms prior to admission | 9.6 (1–20) | 8 | 11 | 0.04 |
| PF ratio | 84 (45–174) | 83 | 85 | 0.9 |
| SOFA Score | 2.9 | 3.3 | 2.5 | 0.005 |
| Pulmonary embolism, No. (%) | 8 (20) | 2 | 6 | 0.14 |
| Intolerance for HFNC, No. (%) | 2 (5) | 2 | 0 | 0.14 |
| Days using HFNO | 5.6 (1–14) | 5.2 | 6 | 0.5 |
| Mortality (%) | 12 | 10(29) | 2(9.5) | 0.003 |
Characteristics of 41 patients with Covid-19 and HFNO treatment admitted to the infection ward at Södersjukhuset, Stockholm, between April and June 2020.
Values are means (interquartile range) unless otherwise stated. P-values for differences across exposure categories were obtained using Fisher's exact test for categorical and Kruskal Wallis for continuous data; COPD, Chronic obstructive pulmonary disease; CRP, C-reactive protein; PF ratio, PaO2/FiO2 ratio; SOFA score sepsis-related organ failure assessment.
a
When the treatment was initiated.